SAB BIOTHERAPEUTICS, INC. Current Assets
SAB BIOTHERAPEUTICS, INC. (SABS) had Current Assets of $107.94 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $107.94M.
- 2026-03-31: Assets, Current $112.78M.
- 2025-12-31: Assets, Current $101.05M; Assets, Current as first filed $101.05M.
- 2025-09-30: Assets, Current $113.28M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $107.94M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $112.78M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $101.05M 10-Q · filed 2026-08-06 | $101.05M 10-K · filed 2026-03-09 |
| 2025-09-30 | $113.28M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $9.31M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $16.30M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $23.79M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $32.54M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $39.58M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $46.95M 10-Q · filed 2024-05-20 | |
| 2023-12-31 | $58.91M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $3.13M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $9.01M 10-Q · filed 2023-08-21 | |
| 2023-03-31 | $15.03M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $22.10M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $22.18M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $28.00M 10-K · filed 2023-04-14 | $27.75M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $37.18M 10-K · filed 2023-04-14 | $36.17M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $50.19M 10-K/A · filed 2023-04-28 | $48.42M 10-K · filed 2022-03-29 |
| 2021-09-30 | $770.62K 10-Q · filed 2021-11-22 | |
| 2021-06-30 | $936.67K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.12M 10-Q · filed 2021-05-21 | |
| 2020-12-31 | $34.46M 10-K/A · filed 2023-04-28 | $87.09K 10-K · filed 2021-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |